These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 32569766)

  • 41. Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
    Jiang N; Xiao Y; Yuan K; Wang Z
    J Gastroenterol Hepatol; 2023 Jul; 38(7):1056-1071. PubMed ID: 36662612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic dysfunction induced by intestinal dysbacteriosis mainly manifests as immunologic abnormity in mice.
    Luo X; Xu B; Xiong T; Su Y; Liu C; Ye Y; Ou M; Zhou L
    Pathog Dis; 2020 Aug; 78(6):. PubMed ID: 32821930
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.
    Ilan Y
    World J Gastroenterol; 2012 Jun; 18(21):2609-18. PubMed ID: 22690069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions between the intestinal microbiome and liver diseases.
    Schnabl B; Brenner DA
    Gastroenterology; 2014 May; 146(6):1513-24. PubMed ID: 24440671
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of gut microbiome in ankylosing spondylitis: an analysis of studies in literature.
    Xu YY; Tan X; He YT; Zhou YY; He XH; Huang RY
    Discov Med; 2016 Dec; 22(123):361-370. PubMed ID: 28147218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
    Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease.
    Stärkel P; Leclercq S; de Timary P; Schnabl B
    Clin Sci (Lond); 2018 Jan; 132(2):199-212. PubMed ID: 29352076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of gut microbiota in intestinal and liver diseases.
    Hrncir T; Hrncirova L; Kverka M; Tlaskalova-Hogenova H
    Lab Anim; 2019 Jun; 53(3):271-280. PubMed ID: 30580671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nod2 Deficiency Leads to a Specific and Transmissible Mucosa-associated Microbial Dysbiosis Which Is Independent of the Mucosal Barrier Defect.
    Al Nabhani Z; Lepage P; Mauny P; Montcuquet N; Roy M; Le Roux K; Dussaillant M; Berrebi D; Hugot JP; Barreau F
    J Crohns Colitis; 2016 Dec; 10(12):1428-1436. PubMed ID: 27147452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease.
    Iyer N; Corr SC
    Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leaky Gut Driven by Dysbiosis Augments Activation and Accumulation of Liver Macrophages
    Zhang H; Liu M; Zhong W; Zheng Y; Li Y; Guo L; Zhang Y; Ran Y; Zhao J; Zhou L; Wang B
    Front Immunol; 2021; 12():624360. PubMed ID: 33841405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota.
    Engen PA; Green SJ; Voigt RM; Forsyth CB; Keshavarzian A
    Alcohol Res; 2015; 37(2):223-36. PubMed ID: 26695747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms and consequences of gut commensal translocation in chronic diseases.
    Fine RL; Manfredo Vieira S; Gilmore MS; Kriegel MA
    Gut Microbes; 2020; 11(2):217-230. PubMed ID: 31306081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of gut microbiota in liver disease.
    Albhaisi SAM; Bajaj JS; Sanyal AJ
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G84-G98. PubMed ID: 31657225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Alteration of intestinal permeability: the missing link between gut microbiota modifications and inflammation in obesity?].
    Genser L; Poitou C; Brot-Laroche É; Rousset M; Vaillant JC; Clément K; Thenet S; Leturque A
    Med Sci (Paris); 2016 May; 32(5):461-9. PubMed ID: 27225918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
    Hendrikx T; Schnabl B
    J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
    Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
    Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gut microbiome and liver diseases.
    Tilg H; Cani PD; Mayer EA
    Gut; 2016 Dec; 65(12):2035-2044. PubMed ID: 27802157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.
    Liu J; Yang D; Wang X; Asare PT; Zhang Q; Na L; Shao L
    Front Cell Infect Microbiol; 2022; 12():774335. PubMed ID: 35444959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.